Evidence map›Paper›PMID 41006500›Full record

ArticleScientific reports2025

An optimized tissue sampling scheme guided by MRI features reveals intratumoral heterogeneity in glioblastoma.

Jun-Han Wang, Ji Xia, Peng-Fei Wu, Liang Yi, Shi-Cang Yu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun-Han Wang *Department of Stem Cell and Regenerative Medicine, Southwest Hospital, Army Medical University, Chongqing, China.
Ji Xia *Department of Neurosurgery, DaPing Hospital, Army Medical University, Chongqing, China.
Peng-Fei WuDepartment of Neurosurgery, DaPing Hospital, Army Medical University, Chongqing, China.
Liang YiDepartment of Neurosurgery, DaPing Hospital, Army Medical University, Chongqing, China. yiliangcq@tmmu.edu.cn.
Shi-Cang YuDepartment of Stem Cell and Regenerative Medicine, Southwest Hospital, Army Medical University, Chongqing, China. yushicang@163.com.

Funding

National Natural Science Foundation of China 82272895National Natural Science Foundation of China 92059204Natural Science Foundation of Chongqing Municipality CSTB2022NSCQ-LZX0061
6 · The paper itself

Abstract

Glioblastoma (GBM) displays marked intratumoral heterogeneity and high invasiveness, making en bloc resection difficult. In particular, total/subtotal resection is challenging for lesions near the diencephalon, midbrain, or brainstem or in motor areas, as damage to these sites can compromise postoperative function and reduce quality of life. Resection of GBM, especially deep-seated tumors, rarely achieves circumferential margins; pathological examination can only be performed on a portion of the tumor. Notably, traditional random intraoperative sampling introduces bias, limiting molecular profiling. The use of imaging-based biomarkers may mitigate this sampling bias, but critical molecular-region signatures remain undefined. In this study, we identified imaging parameters on structural magnetic resonance perfusion imaging to facilitate targeted sampling of representative glioma regions. Whole-exome sequencing of 29 samples from 6 patients revealed significant intratumoral heterogeneity in gene mutations across sampling sites, with edge regions showing the highest heterogeneity. Key cancer driver and drug-target gene mutations also exhibited heterogeneous spatial distributions. Critically, regions with elevated perfusion-weighted imaging cerebral blood volume (PWI-CBV) values demonstrated greater mutation heterogeneity and enrichment of key mutation events. To ensure comprehensive detection of heterogeneous mutations intraoperatively, we propose a three-site sampling strategy within high PWI-CBV regions. This approach may increase the accuracy and completeness of molecular pathological data, ultimately supporting personalized therapeutic planning.

Indexed as

Brain NeoplasmsGlioblastomaMagnetic Resonance ImagingAdultAgedExome SequencingFemaleGenetic HeterogeneityHumansMaleMiddle AgedMutationCerebral blood volumeGlioblastomaIntraoperative samplingIntratumoral heterogeneityMagnetic resonance imaging

Identifiers

PMID41006500
PMCPMC12475489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.